OpenAI plans to take a cut from clients' research achievements in artificial intelligence.

Sarah Frayer, Chief Financial Officer of OpenAI, stated at a special panel discussion at the Davos Forum that in the field of drug development, her company could consider "licensing drugs developed using OpenAI technology." In other words, OpenAI will profit share from the financial gains created by its artificial intelligence for clients. However, she did not provide details on how OpenAI will assist companies in discovering new drugs.